Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral edaravone 96-week safety extension in amyotrophic lateral sclerosis
2020-000376-38Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of edaravone in amyotrophic lateral sclerosis (ALS), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Safety and tolerability of oral edaravone. Started Nov 2020; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2020-000376-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000376-38.